X4 Pharmaceuticals (XFOR) Cash & Equivalents (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Cash & Equivalents for 10 consecutive years, with $195.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 397.44% year-over-year to $195.1 million; the trailing twelve-month figure through Jun 2026 stood at $195.1 million (up 397.44% YoY), and the FY2025 full-year result was $217.0 million, up 289.68% from the prior year.
• Cash & Equivalents declined to $195.1 million in Q2 2026 per XFOR's latest filing, from $216.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $217.0 million in Q4 2025 and bottomed at $39.2 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $106.4 million across 5 years, with a median of $95.4 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents sank 73.36% in 2025, then jumped 438.81% in 2026.
• Over 5 years, Cash & Equivalents stood at $121.7 million in 2022, then decreased by 18.49% to $99.2 million in 2023, then sank by 43.86% to $55.7 million in 2024, then soared by 289.68% to $217.0 million in 2025, then slipped by 10.11% to $195.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $195.1 million, $216.9 million, and $217.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.